The latest type 1 diabetes technology improves the stability of patients' blood sugar levels throughout the day and during sleep, according to a new trial.
A therapy delayed the onset of Type 1 diabetes in at-risk people by about two years, new results from a clinical trial show.
Scientists monitored 106 individuals (some of whom have prediabetes) to see how the condition, and infections, impact immune-and-microbiome-related health.
Results from a multi-center clinical trial show that a drug lowers the risk of kidney failure by a third in people with Type 2 diabetes and kidney disease.
Type 1 diabetes starts out as a sneak attack by bad-actor antibodies. But scientists at Stanford and UCSF have developed an early-warning system.
By delivering a drug directly to beta cells, researchers may be able to spur insulin production and potentially develop a diabetes therapy in the future.
Access and cost of insulin is affecting those who need it most, and without major improvements, millions will be without a treatment, a new study suggests.
Scientists find new potential drug targets for heart disease and diabetes, while shedding more light on the genetics of cholesterol, a new study has found.
Although pioneering scientist Gerald Reaven thought that insulin resistance did not affect the kidney, new research suggests that the story is more complex.
A diabetes program, developed with a Stanford scientist, helps cut costs of diabetes-related health care expenses by $815 per year per person.
A design challenge called Disrupt Diabetes was created and spearheaded by two Stanford seniors — best friends and aspiring doctors who felt that innovations for people with diabetes should bubble up from patients’ daily experiences and priorities.
This video highlights Stanford Health Care's team-based approach to diabetes care. Patient Hazel shares her experience helping to design a treatment plan.
In this final installment of the "Breaking down diabetes" series, physician-researcher Randall Stafford weighs in on a debate about blood sugar levels that relates to drug prices.
In this Breaking Down Diabetes installment, physician-research Randall Stafford clarifies the pros and cons of insulin use in Type 2 diabetes.
This is the fifth in a series of blog posts, by Randall Stafford, MD, PhD discussing prediabetes and Type 2 diabetes.
Diabetes itself has few symptoms, but its consequences can lead to disability and death. Stanford's Randall Stafford breaks down complications.
